Vorasidenib

Drug Overview

Vorasidenib (brand name Voranigo) is a first-in-class, orally bioavailable, brain-penetrant inhibitor of the mutated Isocitrate Dehydrogenase 1 and 2 (IDH1/2) enzymes. It was specifically developed to cross the blood-brain barrier, making it a highly effective targeted therapy for low-grade gliomas that harbor IDH mutations.

In the clinical landscape of March 2026, vorasidenib represents a significant paradigm shift in neuro-oncology. It is the first targeted therapy approved to treat patients with IDH-mutant gliomas, providing a way to delay the need for more aggressive treatments like toxic chemotherapy and radiation. By inhibiting the production of an “oncometabolite” called 2-HG, vorasidenib helps to normalize cell differentiation and slow tumor progression.

• Generic Name: Vorasidenib.
• Brand Name: Voranigo.
• Drug Class: IDH1 and IDH2 Inhibitor.
• Mechanism: Dual inhibition of mutated IDH1 and IDH2 enzymes.
• Route of Administration: Oral (Tablet).
• FDA Approval Status: FDA-approved (Initial approval: August 2024).

What Is It and How Does It Work? (Mechanism of Action)

Vorasidenib targets a specific metabolic “glitch” found in approximately 80% of low-grade gliomas.

1. The IDH Mutation and 2-HG

Normally, IDH enzymes help produce energy in the cell. When these enzymes are mutated, they gain a “neomorphic” (new) function: they start producing massive amounts of a substance called 2-hydroxyglutarate (2-HG).

• The Oncometabolite: 2-HG is considered an “oncometabolite” because its presence blocks the normal maturation of brain cells and promotes the growth of tumors.

2. Molecular Level Mechanisms

1. Enzyme Binding: Vorasidenib binds to both the mutated IDH1 and IDH2 enzymes.
2. Reduction of 2-HG: By blocking these enzymes, vorasidenib dramatically lowers the levels of 2-HG in the brain tumor.
3. Restoring Differentiation: Without high levels of 2-HG, the “block” on cell maturation is lifted. The cancer cells begin to differentiate into more normal-like brain cells, and their ability to proliferate (divide) is significantly reduced.
4. Blood-Brain Barrier Penetration: Unlike earlier IDH inhibitors (like ivosidenib), vorasidenib was engineered to effectively enter the brain, ensuring high concentrations of the drug reach the tumor site.

FDA-Approved Clinical Indications

Vorasidenib is indicated for the treatment of specific adult and pediatric patients with brain tumors.

• IDH-Mutant Glioma: Specifically for adult and pediatric patients (12 years and older) with Grade 2 Astrocytoma or Oligodendroglioma that harbor a susceptible IDH1 or IDH2 mutation.
• Post-Surgery Management: It is typically used following “maximal safe resection” (surgery) to delay the time until further treatments like radiation or chemotherapy are required.

Dosage and Administration Protocols

Vorasidenib is a once-daily oral medication that offers a high degree of convenience compared to traditional IV infusions.

Clinical Efficacy and Research Results

The approval of vorasidenib was driven by the landmark INDIGO Phase 3 clinical trial.

• Progression-Free Survival (PFS): In the trial, patients receiving vorasidenib had a median PFS of 27.7 months, compared to only 11.1 months for those receiving a placebo. This represents a more than doubling of the time the tumor remained stable.
• Delaying Further Treatment: The trial showed that vorasidenib significantly increased the “time to next intervention.” This is crucial for low-grade glioma patients, who are often young and wish to delay the cognitive side effects of radiation for as long as possible.
• Quality of Life: Because the drug is well-tolerated and taken at home, patients maintained a high quality of life while on treatment.

Safety Profile and Side Effects

Vorasidenib has a favorable safety profile, particularly when compared to the intensive regimens of radiation or Temozolomide.

Common Side Effects (>15%):

• Fatigue: The most frequently reported systemic symptom.
• Headache: Often mild and manageable with standard over-the-counter medications.
• Musculoskeletal Pain: Aches in the muscles or joints.
• Diarrhea and Nausea: Generally mild to moderate gastrointestinal upset.

Serious Risks and Lab Abnormalities:

• Hepatotoxicity (Liver Toxicity): The drug can cause elevations in liver enzymes (ALT/AST). Patients require regular blood tests to monitor liver health.
• Nerve/Muscle Toxicity: Rare reports of increased creatine phosphokinase (CPK) levels.
• Pregnancy Risk: Vorasidenib can cause fetal harm; effective contraception is required for both females and males with female partners of reproductive potential.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, vorasidenib is a vital tool for studying “Epigenetic Remodeling.” Because 2-HG causes widespread changes to how DNA is “read” (epigenetics), researchers are using vorasidenib to see if they can “reset” the epigenetic clock of a cancer cell. In 2026, there is also intense interest in “Combination Strategies.” Scientists are investigating if vorasidenib can be used alongside checkpoint inhibitors or targeted vaccines to completely eradicate low-grade gliomas rather than just slowing their growth.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Mutation Testing: A biopsy or surgical sample must be tested to confirm the presence of an IDH1 or IDH2 mutation.
• Liver Function Tests (LFTs): Baseline blood work is mandatory before starting the first dose.

“Do’s and Don’ts” List:

• DO keep your monthly blood-work appointments to check your liver enzymes.
• DO inform your doctor of all other medications, as vorasidenib can interact with “CYP3A” inhibitors or inducers (like certain antibiotics or St. John’s Wort).
• DON’T consume Grapefruit or Seville Oranges, as these can increase the levels of the drug in your blood to dangerous levels.
• DON’T stop taking the medication without consulting your neuro-oncologist, even if you feel fine, as the drug’s effect relies on constant inhibition of the mutated enzyme.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Vorasidenib is a prescription targeted therapy that must be managed by a neuro-oncologist or specialized oncologist. Always consult with your healthcare provider regarding your specific diagnosis and treatment plan.